Viridian Therapeutics, Inc./DE Payments for Restructuring
Viridian Therapeutics, Inc./DE (VRDN) reported Payments for Restructuring of $1.47 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2020-11-12
- Viridian Therapeutics, Inc./DE payments for restructuring for the quarter ending 2020-09-30 was $83.00K.
- Viridian Therapeutics, Inc./DE payments for restructuring for the quarter ending 2020-06-30 was $167.00K.
- Viridian Therapeutics, Inc./DE payments for restructuring for the quarter ending 2020-03-31 was $1.22M.
- Viridian Therapeutics, Inc./DE payments for restructuring for the quarter ending 2019-12-31 was $231.00K.
- Viridian Therapeutics, Inc./DE payments for restructuring for fiscal 2019 was $519.00K.
- Viridian Therapeutics, Inc./DE payments for restructuring for fiscal 2016 was $292.00K.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2020-09-30 | $83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $250.00K derived: sum of 2 quarters · filed 2020-11-12 | $1.47M 10-Q · filed 2020-11-12 | $1.70M derived: sum of 4 quarters · filed 2020-11-12 |
| 2020-06-30 | $167.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.39M 10-Q · filed 2020-08-05 | $1.62M derived: sum of 3 quarters · filed 2020-08-05 | |
| 2020-03-31 | $1.22M 10-Q · filed 2020-05-08 | $1.45M derived: sum of 2 quarters · filed 2020-05-08 | ||
| 2019-12-31 | $231.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $519.00K 10-K · filed 2020-03-13 | ||
| 2019-09-30 | $288.00K 10-Q · filed 2019-11-08 | |||
| 2016-12-31 | $292.00K 10-K · filed 2017-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |